Slide 1: Investor Conference Call H1 2024 Results
Investor Conference Call H1 2024 Results Joachim Kreuzburg, Florian Funck, René Fáber Sartorius | Sartorius Stedim Biotech | July 1 8, 2024
Slide 2: H1 2024: Continued mixed picture
Sartorius Group H 1 2024: Continued mixed picture Demand recovery continues, but not gaining momentum yet; H 1 revenue and margin in line with CMD guidance Bioprocess division: Sales on PY level; recurring business partially still affected by destocking; muted investments in equipment; significa
Slide 3: Agenda
Agenda Sartorius Group H 1 2024 results | FY 2024 guidance Sartorius Stedim Biotech Group H 1 2024 results | FY 2024 guidance Questions & Answers 3
Slide 4: Four years of high volatility and limited visibility; positive trends expected to improve gradually
Sartorius Group Four years of high volatility and limited visibility; positive trends expected to improve gradually Fluctuation order intake vs. H1 19 vs. H1 20 Sales revenue +85% +57% Order intake +58% +23% Sales revenue ex Covid Covid-19 related sales Order intake Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3
Slide 5: Moderate sales decline in H1; Q2 sales slightly up; robust profitability
Sartorius Group Moderate sales decline in H 1 ; Q2 sales slightly up; robust profitability Sartorius Group H 1 2023 H 1 2024 in % in % cc 1 in millions of € unless otherwise specified Sales revenue 1,735 1,680 -3.2 -2.2 Order intake 1,450 1,558 +7.5 +8.5 Underlying EBITDA2 517 471 -8.8 Underlying EB
Slide 6: Regional business performance shows a mixed picture
Sartorius Group Regional business performance shows a mixed picture EMEA Americas Asia | Pacific Sales by region Sales | € in millions Sales | € in millions Sales | € in millions in % +3.6% -6.5% -4.7% EMEA Americas 691 ~41% ~36% 669 646 603 421 387 €1,680m Asia | Pacific H1 2023 H1 2024 H1 2023 H1
Slide 7: Bioprocess Solutions: Increase in order intake; sales revenue at PY level
Sartorius Group Bioprocess Solutions: Increase in order intake; sales revenue at PY level Order intake Sales revenue Underlying EBITDA & margin € in millions € in millions € in millions + 1 1 . 7 % cc -0.2% cc +10.7% -1 . 1 % -6.1% 1,346 1,331 1,102 1,220 414 389 55 400 50 300 45 40 200 30.8 29.2 35
Slide 8: Lab Products & Services: Continues to be affected by soft end markets
Sartorius Group Lab Products & Services: Continues to be affected by soft end markets Order intake Sales revenue Underlying EBITDA & margin € in millions € in millions € in millions -1.5% cc -8.9% cc -2.7% -10.2% -19.4% 348 389 349 338 102 82 26.3 23.6 H 1 2023 H 1 2024 H 1 2023 H 1 2024 H 1 2023 H
Slide 9: Adjusted capex reflected in lower investing cash flow
Sartorius Group Adjusted capex reflected in lower investing cash flow Sartorius Group H1 2023 H1 2024 in % in millions of € unless otherwise specified Underlying EBITDA 517 471 -8.8 Extraordinary items in 2024 driven mainly by Extraordinary items -61 -47 +22.7 reorganization measures and corporate
Slide 10: Balance sheet reflects capital measures; focus on strong cash generation to drive further deleveraging
Sartorius Group Balance sheet reflects capital measures; focus on strong cash generation to drive further deleveraging Key financial indicators Net debt and net debt to underlying EBITDA Sartorius Group Dec. 3 1 , Jun. 30, in millions of € unless otherwise specified 2023 2024 6.0 5,000 5.0 Non-curre
Slide 11: Forecast FY 2024 de-risked in light of persistently high volatility and limited predictability
Sartorius Group Forecast FY 2024 de-risked in light of persistently high volatility and limited predictability; long-term growth drivers remain positive Guidance 2024 1 Sales revenue Underlying EBITDA margin Previous New Previous New on prior-year level Sartorius Group mid- to high single-digit % gr
Slide 12: Agenda
Agenda Sartorius Group H 1 2024 results | FY 2024 guidance Sartorius Stedim Biotech Group H 1 2024 results | FY 2024 guidance Questions & Answers 12
Slide 13: Four years of high volatility and limited visibility; positive trends expected to improve gradually
Sartorius Stedim Biotech Group Four years of high volatility and limited visibility; positive trends expected to improve gradually Fluctuation order intake vs. H1 19 vs. H1 20 Sales revenue +90% +56% Order intake +60% +18% Sales revenue ex Covid Covid-19 related sales Order intake Q1 Q2 Q3 Q4 Q1 Q2
Slide 14: Moderate sales decline in H1; Q2 sales slightly up; robust profitability
Sartorius Stedim Biotech Group Moderate sales decline in H1; Q2 sales slightly up; robust profitability Sartorius Stedim Biotech Group H1 2023 H1 2024 in % in % cc1 in millions of € unless otherwise specified Sales revenue 1,402 1,373 -2.0 -1.2 Order intake 1,142 1,261 +10.4 +11.2 Underlying EBITDA2
Slide 15: Regional business performance shows a mixed picture
Sartorius Stedim Biotech Group Regional business performance shows a mixed picture Asia|Pacific Sales by region EMEA Americas Sales | € in millions in % Sales | € in millions Sales | € in millions +4.4% -6.2% -2.4% EMEA Americas 575 ~ 42% ~ 36% 551 526 492 325 306 €1,373m H1 2023 H1 2024 Asia|Pacifi
Slide 16: Adjusted capex reflected in lower investing cash flow
Sartorius Stedim Biotech Group Adjusted capex reflected in lower investing cash flow Sartorius Stedim Biotech Group H1 2023 H1 2024 in % in millions of € unless otherwise specified Underlying EBITDA 416 387 -6.8 Extraordinary items in 2024 driven mainly by Extraordinary items -50 -28 +44.9 reorgan
Slide 17: Balance sheet reflects capital measures; focus on strong cash generation to drive further deleveraging
Sartorius Stedim Biotech Group Balance sheet reflects capital measures; focus on strong cash generation to drive further deleveraging Key financial indicators Net debt and net debt to underlying EBITDA Sartorius Stedim Biotech Dec. 31, Jun. 30, 4,000 6.0 Group 2023 2024 5.0 in millions of € unless o
Slide 18: Forecast FY 2024 de-risked due to persistently high volatility and limited predictability
Sartorius Stedim Biotech Group Forecast FY 2024 de-risked due to persistently high volatility and limited predictability; long-term growth drivers remain positive Guidance 20241 Sales revenue Underlying EBITDA margin Previous New Previous New on prior-year level Sartorius Stedim Biotech Group mid- t
Slide 19: Questions & Answers
19 Questions & Answers EARTORILS
Slide 20: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee tha